Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 3/20 | 0.55 |
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | BMP4 | P12644 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243349 | 0.82 | SMPD3 (0.51) | SMPD3AXLCDK2IRAK4HSD17B10 | |
| SCHEMBL30579408 | 0.81 | SMPD3 (0.55) | SMPD3AXLCDK2IRAK4HSD17B10 | |
| SCHEMBL22792158 | 0.81 | SMPD3 (0.55) | SMPD3AXLCDK2IRAK4HSD17B10 | |
| SCHEMBL22792265 | 0.81 | SMPD3 (0.50) | SMPD3AXLCDK2IRAK4HSD17B10 | |
| SCHEMBL30579401 | 0.78 | SMPD3 (0.47) | SMPD3AXLCDK2IRAK4HSD17B10 | |
| SCHEMBL29518379 | 0.78 | SMPD3 (0.51) | SMPD3AXLCDK2IRAK4HSD17B10 | |
| SCHEMBL9911040 | 0.76 | KDM4E (0.41) | SMPD3AXLCDK2IRAK4HSD17B10 | |
| SCHEMBL19997258 | 0.75 | HSD17B10 (0.57) | IRAK4HSD17B10ALDH1A1LMNAHPGD | |
| SCHEMBL84781 | 0.75 | SMPD3 (0.60) | SMPD3AXLCDK2IRAK4HSD17B10 | |
| SCHEMBL30837650 | 0.74 | NPSR1 (0.45) | SMPD3AXLIRAK4LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024092011-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023217851-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-κB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
| US-20230027026-A1 | FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-11548890-B1 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2021213317-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-20210087189-A1 | SUBSTITUTED ISINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,3-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20160207940-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2016-07-21 | — | — | US | disclosed |
| WO-2016029776-A1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2016-03-03 | — | — | WO | disclosed |
| US-8940742-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20130267521-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2013-10-10 | — | — | US | disclosed |
| US-20120245162-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-27 | — | — | US | disclosed |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20110245258-A1 | NOVEL ANTIMICROBIALS | PANACEA BIOTEC LTD. (IN) | 2011-10-06 | — | — | US | disclosed |
| US-20080262226-A1 | METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR | ARTESIAN THERAPEUTICS, INC. (CA) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, MC2R | SMPD3 3908/4885AXL 3356/4885CDK2 872/4885 |
| US-11548890-B1 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | SMPD3 1495/4885AXL 3932/4885CDK2 1089/4885 |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | SMPD3 3908/4885AXL 3356/4885CDK2 872/4885 |
| US-20110245258-A1 | NOVEL ANTIMICROBIALS | ECI1, XDH, CYP3A4 | SMPD3 3455/4885AXL 1084/4885CDK2 1665/4885 |
| US-20160207940-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SMPD3 588/4885AXL 1068/4885CDK2 100/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | SMPD3 99/4885AXL 3955/4885CDK2 1989/4885 |
| US-20120245162-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | SMPD3 331/4885AXL 2740/4885CDK2 797/4885 |
| US-20080262226-A1 | METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR | ADRB2, ADRB3, ADRB1 | SMPD3 227/4885AXL 3847/4885CDK2 754/4885 |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | SMPD3 1055/4885AXL 2953/4885CDK2 2685/4885 |
| US-20130267521-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SMPD3 588/4885AXL 1068/4885CDK2 100/4885 |
| US-20210087189-A1 | SUBSTITUTED ISINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,3-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, SIK1 | SMPD3 2706/4885AXL 4469/4885CDK2 346/4885 |
| US-20230027026-A1 | FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | DPYD, TYMP, TYMS | SMPD3 3150/4885AXL 1324/4885CDK2 102/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | SMPD3 2062/4885AXL 2812/4885CDK2 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.